The treatment with IL-12 during pneumonia exerts a protective action via increasing the infiltration of inflammatory cells (ILC1s, NK cells, and neutrophils) and inflammatory cytokines (IFN-γ) (132, 133). The gene discussed is IFNG; the disease is susceptibility to pneumonia measurement.